

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

October 16, 2019

Dennis Mulroy Chief Financial Officer La Jolla Pharmaceutical Company 4550 Towne Centre Court San Diego, CA 92121

Re: La Jolla Pharmaceutical Company
Form 10-K for the Fiscal Year Ended December 31, 2018
Filed March 4, 2019
File No. 001-36282

Dear Mr. Mulroy:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance Office of Life Sciences